{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:10:18Z","timestamp":1784855418650,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":1560,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["29-A-3"],"award-info":[{"award-number":["29-A-3"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["17ck0106348h0001"],"award-info":[{"award-number":["17ck0106348h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["16K09856"],"award-info":[{"award-number":["16K09856"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","exphem.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.exphem.2017.12.006","type":"journal-article","created":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T17:52:21Z","timestamp":1514310741000},"page":"72-81.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Phosphoinositide-dependent protein kinase 1 is a potential novel therapeutic target in mantle cell lymphoma"],"prefix":"10.1016","volume":"59","author":[{"given":"Saori","family":"Maegawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Chinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuna","family":"Tanba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Takimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Matsumura-Kimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeko","family":"Kuwahara-Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Horiike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Taniwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2017.12.006_bib0010","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdg175","article-title":"An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab","volume":"14","author":"Boye","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2017.12.006_bib0015","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2217\/fon.15.57","article-title":"A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas","volume":"11","author":"Feugier","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.exphem.2017.12.006_bib0020","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2017.12.006_bib0025","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","article-title":"Mantle cell lymphoma: evolving management strategies","volume":"125","author":"Campo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.12.006_bib0030","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.12.006_bib0035","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00277-017-2998-6","article-title":"Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO)","volume":"96","author":"Garc\u00eda-Noblejas","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2017.12.006_bib0040","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"LYM-3002 Investigators. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2017.12.006_bib0045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"P\u00e9rez-Gal\u00e1n","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.12.006_bib0050","first-page":"353","article-title":"Clinical management updates in mantle cell lymphoma","volume":"30","author":"Chen","year":"2016","journal-title":"Oncology"},{"key":"10.1016\/j.exphem.2017.12.006_bib0055","doi-asserted-by":"crossref","first-page":"pii: E25","DOI":"10.3390\/cancers9030025","article-title":"Serine\/threonine kinase 3-phosphoinositide-dependent protein kinase-1 (PDK1) as a key regulator of cell migration and cancer dissemination","volume":"9","author":"Di Blasio","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.exphem.2017.12.006_bib0060","doi-asserted-by":"crossref","first-page":"7418","DOI":"10.1158\/0008-5472.CAN-14-1420","article-title":"Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma","volume":"74","author":"Chinen","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2017.12.006_bib0065","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.14707","article-title":"Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1\/RPS6KA3 signalling axis in multiple myeloma","volume":"178","author":"Tatekawa","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2017.12.006_bib0070","article-title":"PDK1: at the crossroad of cancer signaling pathways","author":"Gagliardi","year":"2017","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.exphem.2017.12.006_bib0075","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12032-014-0129-y","article-title":"Prognostic potential of microRNA-138 and its target mRNA PDK1 in sera for patients with non-small cell lung cancer","volume":"31","author":"Han","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.exphem.2017.12.006_bib0080","doi-asserted-by":"crossref","first-page":"29076","DOI":"10.18632\/oncotarget.4931","article-title":"PDK1 induces JunB, EMT, cell migration and invasion in human gallbladder cancer","volume":"6","author":"Lian","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2017.12.006_bib0085","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.bbrc.2015.03.007","article-title":"Phosphoinositide-dependent kinase 1 regulates leukemia stem cell maintenance in MLL-AF9-induced murine acute myeloid leukemia","volume":"459","author":"Hu","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.exphem.2017.12.006_bib0090","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1158\/1541-7786.MCR-09-0179","article-title":"3-phosphoinositide-dependent protein kinase-1 regulates proliferation and survival of cancer cells with an activated mitogen-activated protein kinase pathway","volume":"8","author":"Lu","year":"2010","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.exphem.2017.12.006_bib0095","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/emboj.2013.40","article-title":"PDK1 regulates VDJ recombination, cell-cycle exit and survival during B-cell development","volume":"32","author":"Venigalla","year":"2013","journal-title":"EMBO J"},{"key":"10.1016\/j.exphem.2017.12.006_bib0100","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.12.006_bib0105","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12032-015-0669-9","article-title":"Ibrutinib: from bench side to clinical implications","volume":"32","author":"Grisafi","year":"2015","journal-title":"Med Oncol"},{"key":"10.1016\/j.exphem.2017.12.006_bib0110","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/joim.12600","article-title":"Targeting of B-cell receptor signalling in B-cell malignancies","volume":"282","author":"Jerkeman","year":"2017","journal-title":"J Intern Med"},{"key":"10.1016\/j.exphem.2017.12.006_bib0115","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/0008-5472.CAN-14-2362","article-title":"Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma","volume":"75","author":"Yang","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2017.12.006_bib0120","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/bjh.14780","article-title":"Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions","volume":"179","author":"Moreau","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2017.12.006_bib0125","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1182\/blood-2012-07-439216","article-title":"BTK inhibition in myeloma: targeting the seed and the soil","volume":"120","author":"Edwards","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.12.006_bib0130","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.exphem.2017.12.006_bib0135","doi-asserted-by":"crossref","first-page":"48692","DOI":"10.18632\/oncotarget.8961","article-title":"Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents","volume":"7","author":"Inamdar","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2017.12.006_bib0140","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1038\/bcj.2015.79","article-title":"Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma","volume":"5","author":"Ozaki","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2017.12.006_bib0145","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.exphem.2011.05.002","article-title":"Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression","volume":"39","author":"Sasaki","year":"2011","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2017.12.006_bib0150","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1158\/1535-7163.MCT-12-0605","article-title":"RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma","volume":"11","author":"Shimura","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.exphem.2017.12.006_bib0155","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2017.12.006_bib0160","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.clml.2015.02.029","article-title":"Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study","volume":"15","author":"Panizo","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.exphem.2017.12.006_bib0165","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.12.006_bib0170","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2017.12.006_bib0175","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.12.006_bib0180","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues, World Health Organization classification of tumours","volume":"Vol. 2","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.exphem.2017.12.006_bib0185","doi-asserted-by":"crossref","first-page":"19867","DOI":"10.1074\/jbc.M501367200","article-title":"Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1","volume":"280","author":"Feldman","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2017.12.006_bib0190","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1042\/BJ20101732","article-title":"Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1","volume":"433","author":"Najafov","year":"2011","journal-title":"Biochem J"},{"key":"10.1016\/j.exphem.2017.12.006_bib0195","doi-asserted-by":"crossref","first-page":"27168","DOI":"10.1074\/jbc.274.38.27168","article-title":"90-kDa ribosomal S6 kinase is phosphorylated and activated by 3-phosphoinositide-dependent protein kinase-1","volume":"274","author":"Jensen","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2017.12.006_bib0200","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1158\/0008-5472.CAN-06-4668","article-title":"Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation","volume":"67","author":"Cho","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2017.12.006_bib0205","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/bjc.2017.153","article-title":"Akt as a target for cancer therapy: more is not always better (lessons from studies in mice)","volume":"117","author":"Wang","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.exphem.2017.12.006_bib0210","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/cncr.29363","article-title":"Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: a SWOG cooperative group trial (S1005)","volume":"121","author":"Ramanathan","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2017.12.006_bib0215","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s12272-016-0880-z","article-title":"RSK2 and its binding partners in cell proliferation, transformation and cancer development","volume":"40","author":"Cho","year":"2017","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.exphem.2017.12.006_bib0220","doi-asserted-by":"crossref","first-page":"165","DOI":"10.15430\/JCP.2015.20.3.165","article-title":"Molecular targeting of ERKs\/RSK2 signaling axis in cancer prevention","volume":"20","author":"Yoo","year":"2015","journal-title":"J Cancer Prev"},{"key":"10.1016\/j.exphem.2017.12.006_bib0225","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjh.13487","article-title":"Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies","volume":"170","author":"Roberts","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2017.12.006_bib0230","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2017.12.006_bib0235","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2017.12.006_bib0240","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1038\/sj.onc.1202221","article-title":"Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53","volume":"17","author":"Herrmann","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2017.12.006_bib0245","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/sj.onc.1208300","article-title":"Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM","volume":"24","author":"Tagawa","year":"2005","journal-title":"Oncogene"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X17309050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X17309050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T12:18:48Z","timestamp":1656332328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X17309050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":48,"alternative-id":["S0301472X17309050"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2017.12.006","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphoinositide-dependent protein kinase 1 is a potential novel therapeutic target in mantle cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2017.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 ISEH \u2013 Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}